Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This study uses a CAR T-cell therapy called KTE-X19 — in which a patient's own immune cells are re-engineered to attack cancer cells — in adults with B-cell acute lymphoblastic leukemia (B-ALL) who have responded to initial chemotherapy but still show trace amounts of cancer (called minimal residual disease, or MRD). **You may be eligible if...** - You are 18 or older with B-cell acute lymphoblastic leukemia (a type of blood cancer) - You have achieved a complete response to initial chemotherapy, but a bone marrow biopsy shows trace cancer cells (MRD positive) - Your cancer cells test positive for the CD19 marker - You have recovered from side effects of induction chemotherapy - Your heart, lungs, liver, and kidneys are functioning adequately **You may NOT be eligible if...** - You have a specific type called Burkitt's lymphoma, MLL-rearranged leukemia, or stem cell leukemia - You have an active infection including HIV, Hepatitis B, or Hepatitis C - You have had a heart attack or serious cardiac event in the last 12 months - You have a seizure disorder or have had brain involvement from leukemia - You have another active cancer - You are pregnant or breastfeeding - You have an indwelling drain or catheter (other than approved types) Talk to your doctor to see if this trial is right for you.